NAD+ Not Working? Reasons and Fixes | Real Peptides

NAD+ Not Working? Reasons and Fixes | Real Peptides

You've been taking NAD+ for weeks. Maybe months. And you're not feeling anything. No energy surge. No mental clarity boost. No visible recovery improvement. Our team has reviewed this pattern across hundreds of research protocols in this space, and the culprit is almost never the NAD+ molecule itself. It's one of five delivery, timing, or cofactor errors that make the compound functionally inactive before it ever reaches your mitochondria.

We've guided research teams through this exact troubleshooting process. The gap between an effective NAD+ protocol and one that delivers zero measurable benefit comes down to three things most supplement guides never mention: bioavailability mechanics, enzymatic cofactor dependencies, and cellular uptake timing.

Why isn't my NAD+ supplement working?

NAD+ supplementation fails most often because oral NAD+ has bioavailability of 2–5%. The molecule is too large and polar to cross intestinal membranes intact, so it's degraded in the gut before reaching systemic circulation. Even intravenous NAD+ can fail if administered without magnesium, B3, or methylation support, as NAD+ synthesis and cellular uptake depend on multiple enzymatic pathways that require specific cofactors to function.

Why Oral NAD+ Has Near-Zero Bioavailability

The single biggest reason NAD+ protocols fail is the molecule's size and polarity. NAD+ (nicotinamide adenine dinucleotide) has a molecular weight of 663 Da and carries multiple charged phosphate groups. Making it far too large and hydrophilic to passively cross lipid bilayer membranes in the intestinal wall. When you take oral NAD+, roughly 95–98% is enzymatically degraded by gut microbiota and digestive enzymes before it ever enters circulation. What little survives is further metabolised by the liver during first-pass metabolism.

This is mechanistically different from NAD+ precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), which are smaller, uncharged molecules that can cross cell membranes via specific transporters. NR uses equilibrative nucleoside transporters (ENTs), while NMN appears to utilise the Slc12a8 transporter identified in recent research published in Nature Metabolism. Once inside the cell, these precursors are enzymatically converted to NAD+ through the salvage pathway, bypassing the bioavailability problem entirely. If you're taking straight NAD+ orally and expecting mitochondrial effects, you're working against basic membrane transport physiology.

Our experience shows that researchers switching from oral NAD+ to NMN or NR precursors at equivalent molar doses consistently report measurably different outcomes within 7–14 days. The molecule reaching your cells matters more than the dose on the label. At Real Peptides, we focus on compounds where the delivery mechanism matches the biological target. Because precision at the molecular level determines whether a protocol works or wastes resources.

Cofactor Deficiencies Block NAD+ Synthesis Pathways

Even when NAD+ precursors reach cells successfully, synthesis can still fail if enzymatic cofactors aren't present. NAD+ biosynthesis from NMN or NR requires nicotinamide mononucleotide adenylyltransferase (NMNAT), an enzyme that catalyses the final step of NAD+ assembly. And NMNAT activity depends on ATP and magnesium availability. If intracellular magnesium is depleted (common in high-stress states, chronic alcohol use, or proton pump inhibitor use), NMNAT activity drops, and NAD+ synthesis stalls regardless of precursor availability.

Methylation capacity is the second limiting factor. When NAD+ is consumed by enzymes like PARPs (poly-ADP-ribose polymerases) or sirtuins, it's broken down into nicotinamide, which must be methylated by nicotinamide N-methyltransferase (NNMT) to prevent product inhibition of sirtuin activity. This methylation reaction requires S-adenosylmethionine (SAMe), the universal methyl donor derived from folate and B12 metabolism. If your methylation cycle is impaired. Due to MTHFR polymorphisms, low B12, or inadequate choline intake. Nicotinamide accumulates, sirtuins are inhibited, and the entire reason you're taking NAD+ (sirtuin activation for longevity pathways) is blocked downstream.

Research teams addressing NAD+ not working should verify serum magnesium (RBC magnesium is more accurate than serum), homocysteine levels (elevated homocysteine signals methylation impairment), and B-vitamin status before assuming the NAD+ precursor itself is the problem. We've found that adding 400mg magnesium glycinate and a methylated B-complex (methylfolate + methylcobalamin) alongside NMN restores expected outcomes in protocols that previously showed zero effect.

Timing and Dosage Errors Negate Circadian NAD+ Dynamics

NAD+ levels fluctuate on a circadian rhythm. Peaking in the early morning and declining through the afternoon and evening. This rhythm is driven by the activity of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway, which is transcriptionally regulated by the circadian clock gene BMAL1. Taking NAD+ precursors at the wrong time of day works against this endogenous rhythm rather than supporting it.

Most research protocols dose NMN or NR in the morning (ideally within 30–60 minutes of waking) to amplify the natural NAMPT activity peak and maximise cellular uptake when NAD+-dependent processes like mitochondrial respiration and DNA repair are most active. Evening dosing, by contrast, can disrupt sleep architecture. Elevated NAD+ activates sirtuins, which in turn upregulate genes involved in wakefulness and metabolic activity, making it harder to initiate sleep onset.

Dosage is equally critical. Most commercial NAD+ precursor supplements dose far below the threshold required for measurable sirtuin activation. Research published in Cell Metabolism found that NMN doses below 250mg in humans produced negligible increases in blood NAD+ levels, while doses of 500–1000mg showed dose-dependent increases in circulating NAD+ and NAD+ metabolites. If you're taking 125mg NMN once daily and wondering why nothing's happening, the answer is simple: you're under the effective threshold. Split dosing (250mg morning, 250mg early afternoon) can extend NAD+ elevation across the active day without interfering with evening wind-down.

Comparison Table: NAD+ Delivery Methods and Bioavailability

Different NAD+ delivery methods produce vastly different bioavailability and cellular uptake rates. This table compares oral NAD+, NAD+ precursors, sublingual delivery, and intravenous administration.

Oral NAD+ capsules

2–5%

Degraded by gut enzymes; too large/polar to cross intestinal membranes

Minimal to none

Not recommended. Bioavailability too low for meaningful effect

Oral NMN or NR

40–60% (precursor)

Crosses membranes via specific transporters (Slc12a8 for NMN, ENTs for NR); converted intracellularly

30–90 minutes

Gold standard for daily supplementation. Balances efficacy and practicality

Sublingual NMN

50–70% (precursor)

Bypasses first-pass liver metabolism; absorbed through oral mucosa

15–45 minutes

Faster onset than oral; useful for pre-workout or acute cognitive demands

IV NAD+ infusion

95–100%

Direct bloodstream delivery; no GI degradation

Immediate (during infusion)

Highest bioavailability but requires clinical setting; expensive and impractical for daily use

Liposomal NAD+ or NMN

30–50%

Lipid encapsulation protects from degradation; fuses with cell membranes

45–90 minutes

Moderate improvement over standard oral; cost premium often not justified

Key Takeaways

Oral NAD+ has 2–5% bioavailability because the molecule is too large and polar to cross intestinal membranes. 95% is degraded before reaching circulation.

NAD+ synthesis requires magnesium, ATP, and methylation capacity (SAMe from B12 and folate). Deficiencies in these cofactors block the pathway even when precursors are present.

NMN and NR are smaller precursor molecules that cross membranes via specific transporters and are converted to NAD+ inside cells, bypassing the bioavailability problem.

NAD+ levels follow a circadian rhythm peaking in the morning. Dosing NMN or NR at night can disrupt sleep by activating sirtuin-mediated wakefulness pathways.

Effective NMN dosing starts at 250mg minimum; doses below this threshold produce negligible increases in blood NAD+ levels in human trials.

Methylation impairment from MTHFR polymorphisms, low B12, or inadequate choline allows nicotinamide (NAD+ breakdown product) to accumulate and inhibit sirtuins downstream.

What If: NAD+ Protocol Scenarios

What If I've Been Taking Oral NAD+ for Months and Feel Nothing?

Switch to an NAD+ precursor. NMN or NR. At 250–500mg daily, taken in the morning. Oral NAD+ has near-zero bioavailability, so months of use won't produce mitochondrial effects. Precursors cross cell membranes intact and are converted to NAD+ inside cells where it's needed. You should notice shifts in energy or recovery within 10–14 days if the switch is made correctly.

What If I'm Taking NMN but Still Not Seeing Results?

Verify cofactor status. Specifically magnesium (use RBC magnesium, not serum), homocysteine (elevated signals methylation impairment), and B12. NAD+ synthesis from NMN requires NMNAT enzyme activity, which depends on magnesium and ATP. Methylation of nicotinamide (NAD+ breakdown product) requires SAMe from the folate/B12 cycle. If these are deficient, NAD+ synthesis stalls or sirtuins are inhibited downstream. Add 400mg magnesium glycinate and a methylated B-complex (methylfolate + methylcobalamin) alongside your NMN dose.

What If I Take NMN Before Bed and Can't Sleep?

Move your dose to the morning or early afternoon. NAD+ elevation activates sirtuins, which upregulate genes involved in wakefulness, energy metabolism, and circadian clock entrainment. This works with your body's natural rhythm when dosed in the morning but disrupts sleep onset when taken at night. Split dosing (250mg morning, 250mg 1–2pm) extends NAD+ support across the active day without interfering with evening wind-down.

What If My Dose Is 125mg NMN — Is That Enough?

No. 125mg is below the threshold for measurable NAD+ elevation in most human research. Studies published in Cell Metabolism found that doses below 250mg produced negligible increases in blood NAD+ or NAD+ metabolites, while 500–1000mg showed dose-dependent effects. If budget allows, increase to 250mg minimum; if not, consider that you're likely experiencing placebo rather than pharmacological benefit at the current dose.

The Unfiltered Truth About NAD+ Supplements

Here's the honest answer: most NAD+ supplements sold commercially are either dosed too low to work or formulated in a way that guarantees failure. Oral NAD+ is biologically inert. The molecule cannot cross intestinal membranes, so taking it orally is functionally identical to taking an expensive placebo. Even NMN and NR, which do work when formulated correctly, are often sold at 100–150mg doses that fall below the threshold required for measurable sirtuin activation or mitochondrial benefit.

The marketing around NAD+ leans heavily on longevity research conducted in yeast, worms, and mice. Organisms with dramatically different NAD+ metabolism than humans. A study showing lifespan extension in C. elegans doesn't translate directly to human anti-aging outcomes, and the supplement industry knows this but sells the implication anyway. What does work in humans is NAD+ precursor supplementation at therapeutic doses (500–1000mg NMN or NR daily) combined with cofactor support (magnesium, methylated B-vitamins) and circadian-aligned timing. That's the protocol backed by peer-reviewed human trials published in Nature Metabolism and Cell Metabolism. Everything else is speculative extrapolation.

If your NAD+ protocol isn't working, the problem is almost never that 'NAD+ doesn't work for you'. It's that the formulation, dose, timing, or cofactor status was wrong from the start. Fix those variables before concluding the intervention failed.

Why NAD+ Precursors Outperform Direct NAD+ Supplementation

The bioavailability gap between oral NAD+ and its precursors isn't a minor difference. It's the difference between a functional intervention and a non-intervention. NAD+ precursors like NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are smaller, uncharged molecules that bypass the intestinal degradation pathway entirely by crossing membranes through specific transporters. NMN enters cells via the Slc12a8 transporter, a sodium-dependent channel expressed in the small intestine, liver, and adipose tissue. NR crosses membranes through equilibrative nucleoside transporters (ENTs), which are ubiquitous across human tissues.

Once inside the cell, NMN is converted to NAD+ by nicotinamide mononucleotide adenylyltransferase (NMNAT) in a single enzymatic step. NR requires two steps: phosphorylation to NMN by nicotinamide riboside kinase (NRK), then conversion to NAD+ by NMNAT. Both pathways feed directly into the salvage pathway. The primary route for NAD+ biosynthesis in mammalian cells, responsible for roughly 85% of total NAD+ production. This is why research-grade protocols at institutions studying NAD+ metabolism (Harvard Medical School, Washington University School of Medicine) use NMN or NR rather than direct NAD+. The precursors work with cellular physiology instead of against it.

At Real Peptides, precision synthesis and verified purity are what separate a functional research compound from a mislabeled powder. Our MK 677 and other research peptides follow the same small-batch, exact sequencing standards. Because when the molecule reaching your cells isn't what the label claims, no protocol optimization can fix that.

The information in this article is for educational purposes. Dosage, cofactor supplementation, and protocol decisions should be made in consultation with a licensed healthcare provider familiar with NAD+ metabolism and individual health status.

If your NAD+ protocol has stalled, the fix isn't abandoning the intervention. It's switching to a precursor formulation that crosses membranes, dosing at the threshold backed by human trials (250–500mg minimum), timing the dose to align with circadian NAD+ peaks, and ensuring the cofactors required for synthesis (magnesium, methylated B-vitamins) are present. That's the difference between a protocol that works and one that burns money.

Frequently Asked Questions

Oral NAD+ has bioavailability of only 2–5% because the molecule is too large and polar to cross intestinal membranes — it’s degraded by gut enzymes before reaching circulation. Switch to NAD+ precursors like NMN or NR, which are smaller molecules that cross membranes via specific transporters and are converted to NAD+ inside cells. You should notice measurable shifts in energy or recovery within 10–14 days of switching to a properly dosed precursor (250–500mg daily).

NAD+ is the active coenzyme inside cells, but when taken orally it cannot cross membranes and is degraded in the gut. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are smaller precursor molecules that cross intestinal and cellular membranes via specific transporters (Slc12a8 for NMN, ENTs for NR) and are enzymatically converted to NAD+ once inside cells. Precursors solve the bioavailability problem that makes oral NAD+ ineffective — this is why research institutions studying NAD+ metabolism use NMN or NR rather than direct NAD+ in human trials.

Human trials published in Cell Metabolism found that NMN doses below 250mg produced negligible increases in blood NAD+ levels, while doses of 500–1000mg showed dose-dependent NAD+ elevation and metabolite increases. Most commercial supplements dose at 100–150mg, which falls below the effective threshold. For measurable mitochondrial or sirtuin activation effects, start with 250mg minimum taken in the morning, or split 500mg across morning and early afternoon doses.

NAD+ levels follow a circadian rhythm that peaks in the morning due to NAMPT enzyme activity, which is regulated by the circadian clock gene BMAL1. Taking NMN or NR at night elevates NAD+ when it should naturally decline, activating sirtuins and upregulating wakefulness pathways — this can disrupt sleep onset and architecture. Dose NAD+ precursors in the morning (ideally within 60 minutes of waking) to amplify the natural NAD+ peak and avoid evening administration unless you specifically need metabolic activation for shift work.

NAD+ synthesis from NMN or NR requires magnesium and ATP for NMNAT enzyme activity, plus methylation capacity (SAMe from B12 and folate) to clear nicotinamide breakdown products that inhibit sirtuins. Deficiencies in these cofactors block NAD+ pathways even when precursors are present. Check RBC magnesium (not serum), homocysteine (elevated signals methylation impairment), and B12 levels. Add 400mg magnesium glycinate and a methylated B-complex (methylfolate plus methylcobalamin) if deficiencies are identified.

Three main reasons: (1) dosing below 250mg, which is under the threshold for measurable NAD+ elevation in human trials; (2) cofactor deficiencies (magnesium, B12, folate) that block NAD+ synthesis or downstream sirtuin activity; (3) taking it at the wrong time of day (evening dosing works against circadian NAD+ dynamics). Verify your dose is at least 250mg, take it in the morning, and ensure cofactor status is adequate before concluding NMN doesn’t work for you.

IV NAD+ has near-100% bioavailability because it bypasses the gut entirely, but it requires a clinical setting, costs significantly more per dose, and is impractical for daily long-term use. Oral NMN or NR at 500mg offers 40–60% bioavailability as precursors, which is sufficient for sustained NAD+ elevation when dosed consistently. IV NAD+ makes sense for acute interventions (post-illness recovery, athletic events), but daily oral precursors are more cost-effective and sustainable for ongoing mitochondrial support.

NAD+ is required for mitochondrial ATP production via the electron transport chain and for sirtuin-mediated neuronal health and synaptic function. If low NAD+ levels are contributing to fatigue or cognitive dysfunction, restoring NAD+ via NMN or NR can improve energy and mental clarity — but only if dosed correctly (500mg minimum), timed to circadian rhythms (morning dosing), and supported by adequate cofactors (magnesium, methylated B-vitamins). Energy and cognitive effects typically emerge within 7–14 days of proper supplementation.

NAD+ levels will return to baseline over 7–14 days as exogenous precursor supply is removed and endogenous salvage pathway activity resumes its prior rate. There is no withdrawal or rebound effect — NAD+ precursors support the salvage pathway but do not create dependence. Any benefits related to mitochondrial function, sirtuin activity, or cellular repair will gradually diminish as NAD+ levels normalize to pre-supplementation status.

There is no evidence requiring cycling of NMN or NR — NAD+ is an endogenous coenzyme that turns over constantly, and precursor supplementation simply supports the salvage pathway that already operates continuously in every cell. Long-term human trials (12+ months) show sustained NAD+ elevation without tolerance or diminishing returns. Continuous daily use is both safe and more effective than cycling, as NAD+-dependent processes (mitochondrial respiration, DNA repair, circadian regulation) benefit from sustained elevation rather than intermittent peaks.